Webinar: Parp-Inhibitors and Prostate Cancer - Gotta Have a Mutation??? 06/29/2023

Parp-Inhibitors have long been on AnCan's radar since our dear departed Boardie, Dr. Bill Burhans, found himself with olaparib in his lab in 2015 and convinced his tumor board to prescribe it along with abiraterone for his BRCA2 mutation. Question is ... What's a PARP-Inhibitor, and what does it do? Who benefits from a PARP? Do PARP-I's work for everybody? How can a PARP-I be used for prostate cancer? AnCan brings you two experts to discuss. Dr. Pamela Munster of the UCSF BRCA Research Institute with her unique peer perspective, and Dr. Neal Shore who just released the TALAPRO-2 Study using a PARP with Xtandi. Moderated by beloved AnCan peers, Dr. John Antonucci MD and Len Sierra. SPECIAL THANKS to our sponsors: Bayer, Pfizer Oncology, Myovant Sciences, Foundation Medicine, Myriad Genetics, Janssen - Johnson & Johnson, Telix, and Blue Earth Diagnostics.